Form 4: Amgen EVP David Reese Disposes Shares

Amgen Inc. EVP and Chief Technology Officer David M. Reese disposed of 556 shares of common stock to cover tax obligations.

Summary

• David M. Reese, EVP & Chief Technology Officer of Amgen Inc., sold 556 shares of common stock.
• The transaction occurred on May 7, 2026, at a price of $331.11 per share.
• The total number of shares beneficially owned following the transaction is 42,256.
• The disposal was executed to satisfy tax withholding obligations related to the vesting of equity awards.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the share disposal is purely administrative and related to tax obligations rather than a strategic divestment.

Positives

• The transaction is a routine administrative action related to tax withholding rather than a discretionary market sale.

Negatives

• Reduction in the direct equity stake held by a key executive.

Risks

• None identified; this is a standard regulatory filing for executive compensation tax compliance.

Future Outlook

Not applicable; this is a retrospective disclosure of an insider transaction.

Industry Context

StockSavvy.ai notes that routine Form 4 filings for tax withholding are standard practice in the biotechnology sector and do not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation practices at large-cap pharmaceutical companies like Pfizer, Merck, and Gilead, where equity vesting triggers automatic tax withholding sales.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-discretionary tax-related sale.

Key Dates

Keywords

Amgen, AMGN, Insider Trading, Form 4, Executive Compensation, Biotech